The pivotal role of pathology in the management of lung cancer

Morgan R. Davidson, Adi F. Gazdar, Belinda E. Clarke

Research output: Contribution to journalReview articlepeer-review

120 Scopus citations


The last decade has seen significant advances in our understanding of lung cancer biology and management. Identification of key driver events in lung carcinogenesis has contributed to the development of targeted lung cancer therapies, heralding the era of personalised medicine for lung cancer. As a result, histological subtyping and molecular testing has become of paramount importance, placing increasing demands on often small diagnostic specimens. This has triggered the review and development of the first structured classification of lung cancer in small biopsy/cytology specimens and a new classification of lung adenocarcinoma from the IASLC/ATS/ERS. These have enhanced the clinical relevance of pathological diagnosis, and emphasise the role of the modern surgical pathologist as an integral member of the multidisciplinary team, playing a crucial role in clinical trials and determining appropriate and timely management for patients with lung cancer.

Original languageEnglish (US)
Pages (from-to)S463-S478
JournalJournal of Thoracic Disease
Issue numberSUPPL.5
StatePublished - 2013


  • Lung neoplasms
  • Non-small-cell lung carcinoma (NSCLC)
  • Pathology
  • small cell lung carcinoma (SCLC)

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'The pivotal role of pathology in the management of lung cancer'. Together they form a unique fingerprint.

Cite this